Lasa Supergenerics Ltd - 540702 - Updates on Open Offer
Chartered Finance Management Ltd ("Manager to Open Offer") has submitted to BSE a copy of Post Offer Advertisement under Regulation 18(12) of SEBI (SAST) Regulations, 2011, as amended, for the attention of Equity Shareholders of Lasa Supergenerics Ltd ("Target Company"). Lasa Supergenerics Ltd - 540702 - Updates on Open Offer
Chartered Finance Management Ltd ("Manager to Open Offer") has submitted to BSE a copy of Post Offer Advertisement under Regulation 18(12) of SEBI (SAST) Regulations, 2011, as amended, for the attention of Equity Shareholders of Lasa Supergenerics Ltd ("Target Company"). Lasa Supergenerics Ltd - 540702 - GRANT OF PATENT
We are pleased to announce we have been granted following patents for our key products for the period of 20 years from the date of Filing: 1) AN IMPROVED PROCESS FOR THE PREPARATION OF METHYL 5-(PROPYLTHIO)-1H-BENZOD+ IMIDAZOL-2-YLCARBANATE. 2) PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVE AS ANTHELMINTIC AGENTS. Scanned copy of Patents granted attached for your reference. Till date we have been successfully granted 6 patents and rest 2 are in pipeline. Lasa Supergenerics Ltd - 540702 - Updates on Open Offer
Chartered Finance Management Ltd ("Manager to Open Offer") has submitted to BSE a copy of Offer Opening Public Announcement under Regulation 18(7) of SEBI (SAST) Regulations, 2011, as amended, for the attention of the Shareholders of Lasa Supergenerics Ltd ("Target Company"). Lasa Supergenerics Ltd - 540702 - Updates on Open Offer
Chartered Finance Management Ltd ("Manager to Open Offer") has submitted to BSE a copy of Recommendation of the Committee of Independent Directors ("IDC") of Lasa Supergenerics Ltd ("Target Company") in relation to the Open Offer ("Offer") made to the public shareholders of the Target Company ("Shareholders") under Regulations 3(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended SEBI (SAST) Regulations. Lasa Supergenerics Ltd - 540702 - Announcement under Regulation 30 (LODR)-Allotment
Pursuant to Regulation 30 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation, 2015 and with reference to Board meeting dated August 29,2019 we would like to inform you that Allotment committee of the Board of Directors of the company have allotted 1,78,08,219 equity shares of company to the promoter of the company. In-principal approval under regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 received from BSE and NSE vide their letter dated November 07,2019 and November 29,2019 respectively. Lasa Supergenerics Ltd - 540702 - Compliance Under Regulation 23(9) Of SEBI (Listing Obligations & Disclosure Requirements) Regulations. 2015.
Pursuant to Regulation 23 [9] of the SEBI (Listing obligations and Disclosure Requirements), Regulations, 2015, please find enclosed herewith disclosure of related party transactions for the half- year ended 30 September, 2019. Lasa Supergenerics Ltd - 540702 - Updates on Open Offer
Chartered Finance Management Ltd ("Manager to Open Offer") has submitted to BSE a copy of Corrigendum to Detaild Public Statement published on September 06, 2019 for the attention of Equity Shareholders of Lasa Supergenerics Ltd ("Target Company"). Lasa Supergenerics Ltd - 540702 - Letter of Offer
Chartered Finance Management Ltd ("Manager to Open Offer") has submitted to BSE a copy of Letter of Offer to the Public Equity Shareholders of Lasa Supergenerics Ltd ("Target Company"). Lasa Supergenerics Ltd - 540702 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation, 2015, please find enclosed herewith copies of newspaper advertisements.